Compare ASTRAZENECA PHARMA with WYETH - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs WYETH - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

WYETH 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA WYETH ASTRAZENECA PHARMA/
WYETH
 
P/E (TTM) x 138.1 27.7 498.2% View Chart
P/BV x 38.8 5.3 724.8% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 ASTRAZENECA PHARMA   WYETH
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
WYETH
Mar-13
ASTRAZENECA PHARMA/
WYETH
5-Yr Chart
Click to enlarge
High Rs1,2781,044 122.4%   
Low Rs883818 107.9%   
Sales per share (Unadj.) Rs228.4298.6 76.5%  
Earnings per share (Unadj.) Rs10.457.2 18.1%  
Cash flow per share (Unadj.) Rs16.358.4 27.8%  
Dividends per share (Unadj.) Rs017.00 0.0%  
Dividend yield (eoy) %01.8 0.0%  
Book value per share (Unadj.) Rs98.8249.5 39.6%  
Shares outstanding (eoy) m25.0022.72 110.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.73.1 151.7%   
Avg P/E ratio x104.216.3 640.7%  
P/CF ratio (eoy) x66.415.9 416.8%  
Price / Book Value ratio x10.93.7 293.0%  
Dividend payout %029.7 0.0%   
Avg Mkt Cap Rs m27,00821,157 127.7%   
No. of employees `0001.40.5 275.6%   
Total wages/salary Rs m1,535400 383.8%   
Avg. sales/employee Rs Th4,210.913,787.4 30.5%   
Avg. wages/employee Rs Th1,132.2813.0 139.3%   
Avg. net profit/employee Rs Th191.12,643.3 7.2%   
INCOME DATA
Net Sales Rs m5,7106,783 84.2%  
Other income Rs m123353 34.7%   
Total revenues Rs m5,8337,136 81.7%   
Gross profit Rs m4631,617 28.6%  
Depreciation Rs m14727 554.1%   
Interest Rs m06 0.0%   
Profit before tax Rs m4381,938 22.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m179632 28.3%   
Profit after tax Rs m2591,301 19.9%  
Gross profit margin %8.123.8 34.0%  
Effective tax rate %40.832.6 125.2%   
Net profit margin %4.519.2 23.7%  
BALANCE SHEET DATA
Current assets Rs m3,2096,984 46.0%   
Current liabilities Rs m2,0702,056 100.7%   
Net working cap to sales %20.072.6 27.5%  
Current ratio x1.63.4 45.6%  
Inventory Days Days7299 72.9%  
Debtors Days Days3524 145.9%  
Net fixed assets Rs m790244 323.5%   
Share capital Rs m50227 22.0%   
"Free" reserves Rs m2,4195,441 44.5%   
Net worth Rs m2,4695,668 43.6%   
Long term debt Rs m025 0.0%   
Total assets Rs m4,6057,901 58.3%  
Interest coverage xNM353.3-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.9 144.4%   
Return on assets %5.616.5 34.0%  
Return on equity %10.522.9 45.7%  
Return on capital %17.734.0 52.1%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m30015 1,970.7%   
Fx outflow Rs m2,0152,677 75.3%   
Net fx Rs m-1,715-2,662 64.4%   
CASH FLOW
From Operations Rs m88923 9.5%  
From Investments Rs m-94317 -29.5%  
From Financial Activity Rs mNA-481 0.0%  
Net Cashflow Rs m-6759 -0.8%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 51.1 146.8%  
Indian inst/Mut Fund % 0.3 11.3 2.7%  
FIIs % 15.7 7.2 218.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 30.4 29.9%  
Shareholders   12,856 21,978 58.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   PROCTER & GAMBLE HEALTH  IPCA LABS  NATCO PHARMA  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 300 Points Higher; Dow Futures Up by 39 Points(12:30 pm)

Share markets in India are presently trading on a strong note. The BSE Sensex is trading up by 337 points, up 0.7% at 50,129 levels.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 21, 2021 02:20 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS